Panel Discussion: Building Strategic Vendor Partnerships to Support Seamless Progression from Clinical Development to Commercial Manufacturing

• Selecting vendors with proven capability to scale support from early clinical phases through commercial launch and beyond
• Conducting comprehensive due diligence to evaluate vendor reliability, regulatory compliance, and long-term partnership potential amid evolving market complexities
• Collaborating with automation vendors early in product development to influence their pipelines and ensure tools meet specific biotechnology requirements

Speakers:

Xiangming Li

Associate Director and Director, Bioprocess Development, MSAT, CAR-T Cell Therapy

Cartesian Therapeutics

Lan Le

Executive Director

Aurion Biotech

Margot Molander

Process Development Scientist

Bristol Myers Squibb